Provectus Biopharmaceuticals, Inc. (PVCT) stock
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals, Inc. saw revenue fall 45.5% to $336.11K over fiscal 2025. At the latest close the market valued the company at $20.55M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $20.55M
- P/E ratio
- –
- Price to sales
- 61.15
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $336.11K
- Net income
- -$4.70M
- EPS, diluted
- $0.00
- Book value per share
- -$0.02
- Diluted shares
- 420M
Trading
- Previous close
- $0.05
- Open
- $0.05
- Day's range
- $0.05 – $0.05
- Volume
- 51,200
- Average volume (20 days)
- 67,422
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PVCT | S&P 500 | Difference | PVCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.1% | +0.6% | −11.7 pts | ||
| 3 months | -19.1% | +3.4% | −22.5 pts | ||
| Year to date | -12.5% | +13.3% | −25.8 pts | ||
| 1 year | -35.0% | +16.6% | −51.6 pts | ||
| 3 years | -24.8% | +86.4% | −111.1 pts | -9.1% | +23.1% |
| 5 years | -19.8% | +81.9% | −101.7 pts | -4.3% | +12.7% |
| 10 years | +4.0% | +318.9% | −314.8 pts | +0.4% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Provectus Biopharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- News
- News
- Update
About Provectus Biopharmaceuticals
Pharmaceutical Preparations
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunotherapy medicines for various diseases. The company's drug candidates utilize bioactive, synthetic, pharmaceutical-grade rose bengal sodium, a small molecule within the halogenated xanthenes class. Its clinical programs focus on oncology via intratumoral administration, dermatology through topical formulations, and ophthalmology. Primary investigational candidates include PV-10 for cancer indications such as melanoma and liver cancers, and PH-10 for skin conditions like psoriasis and atopic dermatitis. Provectus conducts clinical trials, expanded access programs, and non-clinical research.
Company profile, executives and historyProvectus Biopharmaceuticals stock: common questions
What is Provectus Biopharmaceuticals's stock price?
PVCT closed at $0.05 on Oct 19, 2026, up 0.39% on the day.
What is Provectus Biopharmaceuticals's market cap?
Provectus Biopharmaceuticals was worth $20.55M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PVCT's P/E ratio?
Provectus Biopharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Provectus Biopharmaceuticals make?
Provectus Biopharmaceuticals reported revenue of $336.11K for fiscal 2025, down 45.5% from a year earlier.
Does Provectus Biopharmaceuticals pay a dividend?
No. Provectus Biopharmaceuticals has not paid a cash dividend over the last twelve months.
How has PVCT stock performed over the past year?
Including dividends, PVCT returned -35.0% over the past year, against +16.6% for the S&P 500.
Who are Provectus Biopharmaceuticals's competitors?
Companies most similar to Provectus Biopharmaceuticals by business, industry and size include INO, ALLR, LIPO, VCNX, RLYB.
See a number that looks wrong?